Reviva Pharmaceuticals Holdings, Inc.
NASDAQ Capital MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Reviva Pharmaceuticals Holdings, Inc. is a late-stage pharmaceutical company engaged in discovering, developing, and commercializing therapeutics primarily for central nervous system, respiratory, and metabolic diseases with significant unmet medical needs. The company's core products include its lead drug candidate brilaroxazine (RP5063), a serotonin/dopamine modulator in clinical development for multiple neuropsychiatric indications such as schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms in Alzheimer's disease and Parkinson’s disease psychosis. Another key product candidate is RP1208, a triple reuptake inhibitor (TRI), targeting similar neuropsychiatric conditions. Additionally, brilaroxazine is being developed for respiratory indications including pulmonary arterial hypertension and idiopathic pulmonary fibrosis. The company uses a chemical genomics-driven technology platform and proprietary chemistry for drug discovery and development. Founded in 2020 and headquartered in Cupertino, California, Reviva Pharmaceuticals focuses on large therapeutic areas such as neuropsychiatric, inflammatory, and cardiometabolic diseases, targeting both U.S. and international markets. Recent major developments include a pre-New Drug Application (NDA) meeting with the U.S. Food and Drug Administration (FDA) planned for Q4 2025 to discuss the approval pathway for brilaroxazine in treating schizophrenia, with a potential NDA submission targeted for Q2 2026. The company has also secured a European patent covering the use of brilaroxazine for schizophrenia and related indications, enhancing intellectual property protection. In 2025, Reviva has reported financial results reflecting narrowing losses and completed a $9 million public offering to support further clinical development and commercialization efforts. Reviva continues to expand its clinical pipeline and strategic focus on transforming treatment options for patients with central nervous system disorders by leveraging innovative drug candidates designed to improve safety and efficacy profiles over existing therapies. The company operates with a strong emphasis on addressing significant unmet medical needs through its integrated chemical genomics approach and maintains ongoing clinical trials to evaluate the safety and efficacy of its lead products across multiple indications.
Reviva to Participate in Fireside Chat at A.G.P.'s Annual Healthcare Company Showcase
Reviva Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Consensus Rating of “Moderate Buy” from Analysts
Reviva Reports Full Year 2025 Financial Results and Recent Business Highlights
What's Behind The Drop In Reviva Pharmaceuticals Stock?
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva to Present at the Sachs 9th Annual Neuroscience Innovation Forum
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Consensus Rating of “Moderate Buy” by Analysts
FDA Asks Reviva Pharmaceuticals To Conduct Additional Phase 3 Study For Its Schizophrenia Drug
Reviva Announces Regulatory Update Regarding the Development of Brilaroxazine for the Treatment of Schizophrenia
Reviva Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Short Interest in Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Rises By 60.7%
Reviva to Present Negative Symptom Data for Brilaroxazine in Schizophrenia from the Phase 3 RECOVER Double-Blind and Open-Label Extension Trials at the CNS Summit 2025
Reviva to Participate in Key Opinion Leader Webinar Hosted by Alliance Global Partners
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
Reviva Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $10 Million Public Offering
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering